Genius Sports Shares Pop On Q2 Earnings Beat
Genius Sports Ltd (NYSE:GENI) reported second-quarter FY22 sales growth of 27.3% year-on-year, to $71.12 million, beating the consensus of $65.26 million.…
Wedbush Maintains Outperform on Albireo Pharma, Lowers Price Target to $61
Wedbush analyst Andreas Argyrides maintains Albireo Pharma (NASDAQ: ALBO) with a Outperform and lowers the price target from $72 to $61.Wedbush analyst Andreas Argyrides maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and lowers the price ta
Jim Cramer Says Don’t Buy This Stock, It’s ‘Losing Money Like Water’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Energizer Holdings, Inc. (NYSE: ENR) is good. He recommended buying the stock.
Baird Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $18
Baird analyst Joel Beatty maintains IDEAYA Biosciences (NASDAQ: IDYA) with a Outperform and lowers the price target from $26 to $18.Baird analyst Joel Beatty maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target fro
Prenetics Launched Circle SnapShot Painless At-Home Blood Tests
Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, announced the launch of Circle SnapShot, a variety of simple, innovative at-home blood tests that provide key insights across 50+ health concerns, including food sensitivity, food allergy, vitamin deficiency, sexual health, heart health,
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
HC Wainwright Slashes PT On This Stock By 50%? Here Are 5 Other Price Target Changes For Tuesday
HC Wainwright & Co. cut the price target on Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) from $10 to $5. HC Wainwright & Co. analyst Patrick Trucchio maintained the stock with a Buy rating. Mind Medicine shares rose 2.3% to $0.7164 in pre-market trading.
HUYA Tops Q2 Despite Macro Headwinds; Margin Shrinks
HUYA Inc (NYSE:HUYA) reported a second-quarter FY22 revenue decline of 23.2% year-on-year to $339.68 million, beating the consensus of $335.88 million.…
Fulcrum Therapeutics Priced ~9.59M Share Public Offering of Common Stock @$7.82/Share
Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share.